Table 1.
Characteristics of included studies.
| Author | Country | Setting | Number of patients | Mean age + SD | Dose of nandrolone | Duration | Iron studies | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Males | Females | Total | Nandrolone | EPO | Total | ||||||
| Navarro et al. [4] | Spain | CAPD | 27 | 0 | 27 | 62 ± 7.00 | 60 ± 8.00 | 61 ± 7.00 | 200 mg/week | 3 months | NR |
| Gascon et al. [5] | Spain | Hemodialysis | 26 | 7 | 33 | 70 ± 4.00 | 72 ± 4.00 | NR | 200 mg/week | 6 months | NS |
| Aggarwal et al. [6] | India | Predialysis | 30 | 0 | 30 | 46 ± 12.61 | 49.90 ± 13.80 | NR | 100 mg/week | 3 months | NS |
| Singh et al. [7] | India | Predialysis | 12 | 12 | 24 | NR | NR | NR | 200 mg/week | 6 months | NS |
Key: CAPD: continuous ambulatory peritoneal dialysis, EPO: erythropoietin, NR: not reported, Iron studies: differences in iron studies at baseline between nandrolone group and EPO group, and NS: not significant.